CMV retinitis is after allogeneic bone marrow transplantation: A report of five cases

Transplant Infectious Disease

Volumn 4, Issue 2, 2002, Pages 75-79

  Larsson, K ^a   Lonnqvist B ^a   Ringden O ^a   Hedquist, B ^b   Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Allogeneic bone marrow transplant; Cytomegalovirus; Retinitis

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLINDNESS; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HUMAN; PRIORITY JOURNAL; RETINITIS; RETROSPECTIVE STUDY; SIBLING; UNIVERSITY HOSPITAL;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS RETINITIS; FEMALE; FOSCARNET; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0036618982     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2002.01018.x     Document Type: Article

References (22)

1. Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A. Ocular complications of heart, lung, and liver transplantation. Br J Ophthalmol 1998: 82: 423-428.
2. Guembel HO, Ohrloff C. Opportunistic infections of the eye in immunocompromised patients. Ophthalmologica 1997: 211: 53-61.
3. Aw MM, Murugasu B, Tan AW, Seah CC, Balakrishnan V, Yap HK. Quantitation of peripheral blood cytomegalovirus DNA for monitoring recurrent cytomegalovirus retinitis in pediatric solid organ transplant recipients. Pediatr Transplant 2000: 4: 100-106.
4. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001: 32: 214-219.
5. Frangieh GT, Dugel PU, Rao NA. Ocular manifestations of acquired immunodeficiency syndrome. Curr Opin Ophthalmol 1992: 3: 228-235.
6. Pertel P, Hirschtick HR, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immun Def Syndr 1992: 5: 1069-1074.
7. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidivudine. J Infect Dis 1992: 166: 1223-1227.
8. Glasgow BJ, Weisberger A. A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency syndrome. Am J Ophthalmol 1994: 118: 46-56.
9. Glasgow BJ. Evidence for breaches of retinal vasculature in acquired immune deficiency syndrome angiopathy. A fluorescent microsphere study. Ophthalmology 1997: 104: 753-760.
10. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with AIDS. Am J Ophthalmol 1993: 115: 574-582.
11. Kaulfersch W, Urban C, Hauer C, et al. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation. Bone Marrow Transplant 1989: 4: 587-589.
12. McAucliffe PF, Hall MJ, Castro-Malaspina H, Heinemann MH. Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation. Am J Ophthalmol 1997: 123: 702-703.
13. Suzuki N, Kudoh T, Mizue N, et al. CMV retinitis after cessation of ganciclovir therapy for CMV antigenemia in an unrelated BMT recipient. Bone Marrow Transplant 1998: 22: 931-932.
14. Ringdén O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporine and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991: 7: 221-226.
15. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994: 83: 2723-2730.
16. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B, and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995: 15: 619-625.
17. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994: 14: 601-607.
18. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998: 66: 1330-1334.
19. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996: 17: 583-587.
20. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997: 19: 241-248.
21. Small TN, Papadoupoulos E, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999: 93: 467-480.
22. Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995: 16: 401-405.